Bharath Biotech has maintained a rather low profile since its operations in 1996. Low profile but with high productivity, because it has 160 patents to its credit and has introduced vaccines for more than a dozen diseases like Hib , Poliomyelitis, Diphtheria, Tetanus, Pertussis, H1N1, Rabies, Japanese Encephalitis, Hepatitis B, Rotavirus and Typhoid. With this brilliant track record in the biotech domain, it is not surprising that Bharath Biotech today has manufactured COVAXIN India’s ‘first’ indigenous COVID-19 vaccine, developed in collaboration with University of Wisconsin, the Indian Council of Medical Research (ICMR), Thomas Jefferson University and the National Institute of Virology (NIV). Drug Controller General of India (DCGI) has given the go ahead to conduct human trials with COVAXIN. Hearty congratulations to Dr.Krishna M.Ella and his wife Suchitra Ella who returned from US two decades back to lead innovation and their fight against mankind’s dreaded diseases globally from Hyderabad. We keep our fingers crossed for a safe outcome of the human trials. Mera Bharath Mahan.
BhaskarChakravorti 